Palliative local radiotherapy in the treatment of tumor-stage cutaneous T-cell lymphoma/mycosis fungoides.
OBJECTIVE
To determine the efficacy of palliative radiotherapy in treating tumor-stage cutaneous T-cell lymphoma/mycosis fungoides (MF).


METHODS
From January 2008 to January 2013, a total of 11 patients with tumor-stage MF were treated with local radiation therapy in Peking Union Medical College Hospital. The median age of these patients was 53.36 ± 14.45 years. Female-male ratio was 1:1.2. The average course of disease was 10.82 ± 3.37 years. All the patients were treated with local electronic beam irradiation with a total median dosage of 48.55 ± 9.51 (40-74) Gy in an average of 24.55 ± 5.57 (20-40) fractions, 5 fractions per week.


RESULTS
The median follow-up time was 55.27 ± 29.3 (13-103) months. No severe acute or chronic side effects of irradiation were observed. Complete clinical response (CR) rate of the radiated sites was 54.5% (6/11), partial response (PR) rate was 36.4% (4/11), and the overall response rate (CR+PR) was 90.9%. One patient showed no response.


CONCLUSIONS
Local radiotherapy with psolaren plus ultraviolet A and/or interferon maintaining treatment is an effective palliative therapy in the treatment of tumor-stage MF patients.
Department of Dermatology, Peking Union Medical College Hospital, Chinese; Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Chen-chen
CC
Xu
Department of Dermatology, Peking Union Medical College Hospital, Chinese; Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Tao
T
Zhang
Department of Dermatology, Peking Union Medical College Hospital, Chinese; Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Tao
T
Wang
Department of Dermatology, Peking Union Medical College Hospital, Chinese; Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Jie
J
Liu
Department of Dermatology, Peking Union Medical College Hospital, Chinese; Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Yue-hua
YH
Liu
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D059186:Chemoradiotherapy, Adjuvant / Q000379:methods; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D011701:PUVA Therapy / Q000379:methods; D010166:Palliative Care / Q000379:methods*; D011879:Radiotherapy Dosage; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007372:Interferons